FDA Part 207 Guide for Foreign OTC Drug Manufacturers

Every year I hear a version of the same story from a UK or EU manufacturer: they've built a beautiful SPF skincare line, it's compliant with the EU Cosmetics Regulation, their facility runs to ISO 22716, and they've just landed a US retail listing for two products. Then someone on their team reads 21 CFR Part 207 for the first time and realizes none of that European paperwork transfers. In the United States, sunscreen isn't a cosmetic. It's an over-the-counter drug, and the moment your product crosses that line, you're inside FDA's drug establishment registration and listing system whether you built for it or not.

This guide walks through what 21 CFR Part 207 actually requires of a non-US OTC manufacturer, clause by clause, including the parts that trip up sunscreen and other monograph-drug exporters specifically.

What 21 CFR Part 207 Actually Covers

Part 207 — "Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs" — was recodified in 2016 to move the whole system onto electronic, standardized submissions. It's organized into subparts that matter in a specific order for a foreign manufacturer: Subpart B governs who registers and when, Subpart C governs the National Drug Code (NDC) that identifies every product, Subpart D governs drug listing itself, and Subpart F sets the rules for your official contact and US Agent. If you manufacture, repack, relabel, or salvage a drug — including an OTC monograph drug like a sunscreen, antiseptic, or acne treatment — that is imported or offered for import into the US, Part 207 applies to your facility, not just to the company that puts its name on the bottle.

It's worth saying plainly what Part 207 is not: it is not premarket approval. FDA does not review your registration or listing submission for scientific accuracy before it's accepted into the system. Registering a facility and listing a drug tells FDA you exist and what you're shipping — it doesn't tell FDA, or your customers, that the product is safe or effective. That determination happens elsewhere, and for OTC drugs it usually happens through the monograph system, which is the part most beauty-industry exporters have never had to think about.

Is Your Product Actually a Drug? The SPF Trap

Sunscreen is the clearest example of a broader problem: US and EU/UK regulatory categories for the same physical product don't match. In the UK and EU, sunscreen is a cosmetic, regulated for safety substantiation under the EU Cosmetic Products Regulation. In the US, sunscreen is an OTC drug under the FD&C Act, regulated through what's now called the nonprescription sunscreen monograph (established under section 505G, added by the CARES Act in 2020, covering conditions FDA had already recognized through the older OTC Drug Review as monograph M020).

That reclassification carries a consequence that catches almost every European SPF brand off guard: the list of UV filters approved for US sunscreens is much shorter than the list approved in the EU. Of the sixteen active ingredients FDA has historically recognized in the US sunscreen monograph, only zinc oxide and titanium dioxide currently carry FDA's default "generally recognized as safe and effective" status without additional safety data; most of the others, including chemical filters common in European formulations such as avobenzone and octocrylene, remain under FDA review pending more data, and newer European filters like Tinosorb and Uvinul were never added to the US monograph at all. Registering your establishment and listing your product under Part 207 does nothing to solve this — if your formulation relies on a filter that isn't on the US monograph list, you have a reformulation problem, not a paperwork problem, and it needs to be identified before you spend time on registration at all.

Who Must Register Under §207.17

Under 21 CFR 207.17, every foreign establishment that manufactures, repacks, relabels, or salvages a drug that is imported or offered for import into the United States must register — unless an exemption applies. The most common exemptions a contract manufacturer should check: the drug undergoes further manufacturing or processing at a different foreign establishment before importation (in which case that downstream establishment registers instead), or another party in the supply chain has already registered for that specific drug at that specific site. Ownership of the brand doesn't determine who registers — the physical site where manufacturing, repacking, relabeling, or salvaging occurs does. If you're a UK contract manufacturer producing private-label SPF product for three different US brand owners, your facility registers once; the individual brand owners handle drug listing for their own labeled products manufactured at your site.

The Registration Process, Step by Step

1. Obtain a DUNS number. FDA's registration system still requires a Dun & Bradstreet Data Universal Numbering System (DUNS) number as your facility's unique identifier. Apply early — this is the step most foreign manufacturers underestimate on timeline.

2. Create an FDA account in FURLS/DRLS. Foreign establishments register and list drugs through FDA's Drug Registration and Listing System (DRLS), accessed via the FDA Unified Registration and Listing System (FURLS) portal, using Structured Product Labeling (SPL) format for the listing data itself.

3. Designate an Official Contact and a US Agent. Under 21 CFR 207.69, every registrant must name an Official Contact responsible for the accuracy of registration and listing information, and every foreign establishment must additionally designate a single United States Agent. The regulation is specific about what counts: the US Agent "must reside or maintain a place of business in the United States and may not be a mailbox, answering machine or service, or other place where a person acting as the United States agent is not physically present." A virtual mailbox service or a shell LLC with no staff will not satisfy FDA on inspection.

4. Register the establishment before importation. This is where foreign and domestic timelines diverge in a way that catches people out. A domestic establishment has a grace period — it must register no later than five calendar days after beginning to manufacture, repack, relabel, or salvage a drug. A foreign establishment gets no such grace period: under 21 CFR 207.21, registration must occur before the drug is imported or offered for import into the United States. There's no five-day buffer to lean on if you're shipping from overseas.

5. List each drug within three calendar days of initial registration. Under 21 CFR 207.45, listing information for every drug being manufactured for commercial distribution at the time of your establishment's initial registration is due no later than three calendar days after that registration. Each product needs a National Drug Code (NDC) under 21 CFR 207.33 — a unique identifier tied to labeler, product, and package size — obtained through the same DRLS system.

6. Renew annually, not biennially. This is one of the most common points of confusion, because it gets mixed up with the two-year cycle that applies to food facility registration under a different part of the CFR entirely. Drug establishment registration under 21 CFR 207.29 is an annual obligation: the first review and update occurs during the period from October 1 through December 31 of the year of initial registration if that registration happened before October 1, and every subsequent year follows the same October 1–December 31 window. If nothing has changed, you still have to certify that nothing has changed — silence is not an acceptable response.

7. Confirm whether the OTC Monograph Drug User Fee applies to you. If your product is regulated under the OTC monograph system — as sunscreen is — your facility may owe an annual facility fee under the OTC Monograph Drug User Fee program (OMUFA), separate from Part 207 registration itself. For fiscal year 2025, FDA set the fee at $37,556 for a monograph drug facility (MDF) and $25,037 for a contract manufacturing organization (CMO) tier, and these rates reset every October 1, so budget for the current-year figure rather than an old one you found in a blog post.

OTC Drug Rules vs. the Frameworks You Already Know

Foreign beauty and personal care manufacturers usually arrive with fluency in cosmetic or food frameworks, and it's worth seeing where drug rules actually diverge from those.

The row that matters most for a beauty-industry exporter is the GMP standard. ISO 22716, the cosmetic GMP standard most UK and EU manufacturers already run, does not satisfy FDA's drug current Good Manufacturing Practice requirements under 21 CFR Parts 210 and 211. The two systems overlap on hygiene and documentation basics, but drug cGMP adds requirements — validated cleaning, formal batch record review and release, stability programs, deviation and CAPA systems — that a cosmetics-only quality system usually hasn't built out. Registering under Part 207 puts your facility on FDA's radar for inspection against that standard, not against the one you're already certified to.

What Happens If You Skip It

The consequences aren't abstract. A drug manufactured at an unregistered establishment, or shipped without being properly listed, is misbranded under section 502(o) of the FD&C Act by virtue of the registration or listing failure alone — independent of whether the product itself is safe or well-made. FDA also has express statutory authority under section 801(a)(3) to refuse admission of a drug manufactured, prepared, propagated, compounded, or processed at an establishment not duly registered. In practice, that shows up as detention without physical examination at the port of entry, placement on an FDA import alert affecting every future shipment from your site, or a warning letter that becomes public and gets read by every retail buyer doing due diligence on your company afterward. None of these outcomes require FDA to have ever set foot in your facility — registration and listing failures are documentary, and they're checked at the border before your product ever reaches a shelf.

A Compliance Checklist for Foreign OTC Manufacturers

• Confirm your product's actual US regulatory classification before assuming a cosmetic or supplement framework applies — sunscreen, antiseptic, antiperspirant, and many acne and anti-dandruff products are OTC drugs in the US regardless of how they're classified at home.
• For sunscreen specifically, cross-check every active UV filter against the current US monograph list before committing to registration — a formulation built around a European-only filter needs reformulation, not paperwork.
• Obtain a DUNS number early; it's the long-pole item most manufacturers underestimate.
• Set up your FURLS/DRLS account and confirm who at your organization owns SPL submissions going forward.
• Designate a US Agent with an actual physical US presence — not a mail forwarding service — and a separate Official Contact responsible for data accuracy.
• Register your establishment before the first shipment leaves for the US; there is no grace period for foreign sites.
• List every drug within three calendar days of initial registration and obtain NDC numbers for each.
• Calendar the annual October 1–December 31 renewal window every year, and certify "no change" if nothing has changed.
• Determine whether OMUFA facility fees apply and budget for the current fiscal year's rate.
• Run a gap assessment of your quality system against 21 CFR Parts 210/211 before assuming ISO 22716 compliance is close enough.

FAQ

Does FDA approve my product when I register under 21 CFR Part 207? No. Registration and listing are notification requirements, not premarket approval. An OTC drug is marketed lawfully by conforming to an applicable monograph's conditions on active ingredients, dosage, and labeling — FDA doesn't review or approve your specific formulation before it's sold.

Is drug establishment registration biennial like food facility registration? No, and this is one of the most common mix-ups. Food facility registration under a different part of the CFR runs on a two-year cycle. Drug establishment registration under 21 CFR 207.29 is annual, renewed every October 1 through December 31.

Do I still need a US Agent if I already sell through a US-based distributor? Yes. The US Agent requirement under 21 CFR 207.69 attaches to the registrant of the foreign establishment, not to your distribution arrangement. A distributor relationship doesn't substitute for a designated US Agent with a genuine physical US presence.

Is sunscreen really regulated as a drug in the US even though it's a cosmetic in the UK and EU? Yes. US law treats any product marketed with a drug claim — including sun protection — as an OTC drug regulated through the sunscreen monograph, regardless of how the same formulation is classified in other markets.

What's the real risk if I sell into the US without registering or listing my product? Your product becomes misbranded under FD&C Act section 502(o), and FDA can refuse it admission at the border under section 801(a)(3) — independent of product quality. That typically means detention, an import alert affecting future shipments, or a public warning letter.

If your facility is heading toward a US launch and you're not sure whether Part 207, the OTC monograph, or straightforward drug cGMP applies to what you're making, that's exactly the kind of question worth working through before the first shipment is scheduled rather than after it's detained. Our step-by-step guide to becoming GMP compliant walks through the quality-system side of that gap, and you're welcome to reach out directly if you want a second set of eyes on your specific registration and listing plan.

Last updated: 2026-08-04